Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series
Marc Scherlinger(Inserm), Sibilia Jean(Inserm), S. Hilliquin(Inserm), Yannick Dieudonné(Inserm), Vincent Gies(Inserm), Célestine Simand(Hôpitaux Universitaires de Strasbourg), Emmanuel Chatelus(Laboratoire National de Référence), Justine Decroocq(Centre National de la Recherche Scientifique), E. Sebbag(Hôpital d'Hautepierre), A. El Aatmani(Hôpitaux Universitaires de Strasbourg), Roberto D’Alessandro(Inserm), Thierry Martin(Inserm), Yannick Allanore(Inserm), Jacques-Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), Benoît Nespola(Hôpitaux Universitaires de Strasbourg), Marie Laure Brandely-Piat(Hôpital Cochin)
Cited by 5
Related Papers
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
|Blood|2015|383
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
|Haematologica|2021|181